FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385514797> ?p ?o ?g. }

• W4385514797 endingPage "367" @default.
• W4385514797 startingPage "358" @default.
• W4385514797 abstract "Biologic agents are emerging as an important treatment option for immune-mediated diseases. Injection site reactions following subcutaneous injection of biologic agents is not well described in the literature.To summarize injection site reaction data in phase 3 trials of all biologic agents.MEDLINE, Embase, and CENTRAL databases were systematically searched on February 8, 2022. Proportional meta-analysis was conducted to summarize injection site reaction prevalence for each biologic.There were 158 articles included in the review. The most common types of injection site reactions were erythema (42.8%), unspecified reaction (23.3%), pain (12.4%), and pruritus (5.7%). No patients discontinued their treatment due to injection site reactions in 39 of the 48 studies that reported on discontinuation data. There were 16 biologics included in meta-analysis across 80 eligible studies. The biologics with the highest point prevalence of patients reporting injection site reactions were Canakinumab (15.5%; 294 patients), Dupilumab (11.4%; 1888 patients), Etanercept (11.4%; 4363 patients), and Ixekizumab (11.2%; 2205 patients). The biologics with the lowest point prevalence of injection site reactions were Risankizumab (0.8%; 707 patients), Brodalumab (1.3%; 1365 patients), Guselkumab (1.3%; 1852 patients), Secukinumab (1.9%; 1277 patients).The prevalence of injection site reaction in response to biologics ranges from 0.08 to 15.5%. Canakinumab, Dupilumab, Etanercept, and Ixekizumab had the highest prevalence of injection site reactions. Risankizumab, Brodalumab, Guselkumab, and Secukinumab had the lowest prevalence of injection site reactions. Recommendations are made regarding the improvement of adverse event reporting to better understand the epidemiology of injection site reactions." @default.
• W4385514797 created "2023-08-04" @default.
• W4385514797 creator A5000030131 @default.
• W4385514797 creator A5009572165 @default.
• W4385514797 creator A5077651202 @default.
• W4385514797 date "2023-07-01" @default.
• W4385514797 modified "2023-09-27" @default.
• W4385514797 title "A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections" @default.
• W4385514797 cites W1524130381 @default.
• W4385514797 cites W163720670 @default.
• W4385514797 cites W1951996485 @default.
• W4385514797 cites W1967330688 @default.
• W4385514797 cites W1975107434 @default.
• W4385514797 cites W1989015253 @default.
• W4385514797 cites W1991810959 @default.
• W4385514797 cites W2012515921 @default.
• W4385514797 cites W2017200913 @default.
• W4385514797 cites W2080661980 @default.
• W4385514797 cites W2602199935 @default.
• W4385514797 cites W2779299343 @default.
• W4385514797 cites W2910866765 @default.
• W4385514797 cites W2919004480 @default.
• W4385514797 cites W2922629246 @default.
• W4385514797 cites W2987988892 @default.
• W4385514797 cites W3118615836 @default.
• W4385514797 cites W3154471392 @default.
• W4385514797 cites W3200920720 @default.
• W4385514797 cites W4224235205 @default.
• W4385514797 doi "https://doi.org/10.1177/12034754231188444" @default.
• W4385514797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37533141" @default.
• W4385514797 hasPublicationYear "2023" @default.
• W4385514797 type Work @default.
• W4385514797 citedByCount "0" @default.
• W4385514797 crossrefType "journal-article" @default.
• W4385514797 hasAuthorship W4385514797A5000030131 @default.
• W4385514797 hasAuthorship W4385514797A5009572165 @default.
• W4385514797 hasAuthorship W4385514797A5077651202 @default.
• W4385514797 hasBestOaLocation W43855147971 @default.
• W4385514797 hasConcept C126322002 @default.
• W4385514797 hasConcept C16005928 @default.
• W4385514797 hasConcept C168563851 @default.
• W4385514797 hasConcept C197934379 @default.
• W4385514797 hasConcept C203014093 @default.
• W4385514797 hasConcept C203092338 @default.
• W4385514797 hasConcept C2776260265 @default.
• W4385514797 hasConcept C2777226972 @default.
• W4385514797 hasConcept C2777575956 @default.
• W4385514797 hasConcept C2778715236 @default.
• W4385514797 hasConcept C2778975655 @default.
• W4385514797 hasConcept C2779121184 @default.
• W4385514797 hasConcept C2779134260 @default.
• W4385514797 hasConcept C2779725882 @default.
• W4385514797 hasConcept C2779745271 @default.
• W4385514797 hasConcept C2779786854 @default.
• W4385514797 hasConcept C2780132546 @default.
• W4385514797 hasConcept C2780564577 @default.
• W4385514797 hasConcept C2781228260 @default.
• W4385514797 hasConcept C2908959886 @default.
• W4385514797 hasConcept C2910384678 @default.
• W4385514797 hasConcept C3018125106 @default.
• W4385514797 hasConcept C512399662 @default.
• W4385514797 hasConcept C71924100 @default.
• W4385514797 hasConcept C95190672 @default.
• W4385514797 hasConceptScore W4385514797C126322002 @default.
• W4385514797 hasConceptScore W4385514797C16005928 @default.
• W4385514797 hasConceptScore W4385514797C168563851 @default.
• W4385514797 hasConceptScore W4385514797C197934379 @default.
• W4385514797 hasConceptScore W4385514797C203014093 @default.
• W4385514797 hasConceptScore W4385514797C203092338 @default.
• W4385514797 hasConceptScore W4385514797C2776260265 @default.
• W4385514797 hasConceptScore W4385514797C2777226972 @default.
• W4385514797 hasConceptScore W4385514797C2777575956 @default.
• W4385514797 hasConceptScore W4385514797C2778715236 @default.
• W4385514797 hasConceptScore W4385514797C2778975655 @default.
• W4385514797 hasConceptScore W4385514797C2779121184 @default.
• W4385514797 hasConceptScore W4385514797C2779134260 @default.
• W4385514797 hasConceptScore W4385514797C2779725882 @default.
• W4385514797 hasConceptScore W4385514797C2779745271 @default.
• W4385514797 hasConceptScore W4385514797C2779786854 @default.
• W4385514797 hasConceptScore W4385514797C2780132546 @default.
• W4385514797 hasConceptScore W4385514797C2780564577 @default.
• W4385514797 hasConceptScore W4385514797C2781228260 @default.
• W4385514797 hasConceptScore W4385514797C2908959886 @default.
• W4385514797 hasConceptScore W4385514797C2910384678 @default.
• W4385514797 hasConceptScore W4385514797C3018125106 @default.
• W4385514797 hasConceptScore W4385514797C512399662 @default.
• W4385514797 hasConceptScore W4385514797C71924100 @default.
• W4385514797 hasConceptScore W4385514797C95190672 @default.
• W4385514797 hasIssue "4" @default.
• W4385514797 hasLocation W43855147971 @default.
• W4385514797 hasLocation W43855147972 @default.
• W4385514797 hasOpenAccess W4385514797 @default.
• W4385514797 hasPrimaryLocation W43855147971 @default.
• W4385514797 hasRelatedWork W2202409929 @default.
• W4385514797 hasRelatedWork W2517289120 @default.
• W4385514797 hasRelatedWork W2781621836 @default.
• W4385514797 hasRelatedWork W2984218665 @default.
• W4385514797 hasRelatedWork W3042976130 @default.

• next